ArticleFrontiers in human neuroscience2026
YOLOBT: a novel ERP bad trial detection network dynamically adjusting based on global signal quality.
Article in Frontiers in human neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Event-related potentials (ERPs) are time-locked voltage changes in averaged EEG signals reflecting neural responses to specific events. ERPs are extracted from EEG by repeating the same stimulus across multiple trials and averaging the recordings. In ERP studies, artifact-contaminated trials (commonly termed "bad trials") refer to data segments deemed unsuitable for analysis due to excessive noise or artifacts. The criteria for determining such trials depend on overall data quality: researchers increase artifact tolerance when a subject's data quality is poor to retain statistical power, while applying stricter standards when quality is high to ensure analytical purity and accuracy. Current automated bad trial detection methods rely on static thresholds and fail to replicate the adaptive strategies employed by experts. To address this limitation, we propose YOLOBT, a YOLO-based deep learning framework that mimics expert judgment by integrating global signal quality assessment with dynamic threshold adjustment. By treating EEG signals as visualized waveform images, our approach naturally aligns with expert visual inspection methods while enabling context-aware artifact detection. Our technical contributions include: (1) a Cross-Layer Attention Bottleneck (CLAB) enhancing artifact feature extraction through cross-layer attention mechanisms; (2) a Hierarchical Feature Guidance Module (HFGM) leveraging high-level semantic features to guide low-level feature refinement; and (3) a Global Information Classification Module (GICM) enabling dynamic threshold adjustment based on comprehensive signal quality assessment. Experiments on our manually annotated dataset showed YOLOBT achieved 88.76% precision, 86.89% recall, 92.76% mAP, and 87.82% F1 score, outperforming classical models. Heatmap visualization confirmed the model adaptively adjusts artifact detection strategies based on signal quality, similar to expert judgment processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.